ISCHEM Corporation (ISCHEM) is a medical company that provides proprietary diagnostic, prognostic, and therapeutic products for the “vulnerable” person in the heart disease and stroke market place. ISCHEM has two initial cost-saving products under development that non-invasively identify and for the first time manage an asymptomatic individual’s “vulnerability” to heart attack and stroke.  These initial products are made by applying proprietary breakthrough data-analytic and statistical methods (e.g., neural network technologies and statistical artifact detection) to outcome data from landmark studies with extensive databases of medical histories.